Targeted degradation of Pin1 by an antagonistic peptide enhances gemcitabine therapy in pancreatic cancer.
1/5 보강
Targeted protein degradation (TPD) has emerged as a powerful strategy for eliminating disease-causing proteins.
APA
Chen M, Chu X, et al. (2025). Targeted degradation of Pin1 by an antagonistic peptide enhances gemcitabine therapy in pancreatic cancer.. RSC medicinal chemistry. https://doi.org/10.1039/d5md00970g
MLA
Chen M, et al.. "Targeted degradation of Pin1 by an antagonistic peptide enhances gemcitabine therapy in pancreatic cancer.." RSC medicinal chemistry, 2025.
PMID
41574233 ↗
Abstract 한글 요약
Targeted protein degradation (TPD) has emerged as a powerful strategy for eliminating disease-causing proteins. The prolyl isomerase Pin1 is an attractive therapeutic target given its oncogenic function. Here, we develop PIPWF, a novel peptide degrader that induces Pin1 degradation through multivalent binding and conformational destabilization. Pin1 degradation attenuates cancer-associated fibroblast (CAF) activation to reshape the fibrotic tumor microenvironment and enhance chemosensitivity ENT1-mediated gemcitabine uptake. results demonstrated that both PIPWF and its nanoformulation M-PIPWF synergized with gemcitabine to induce tumor regression and prolong survival, illustrating a novel peptide-based TPD strategy against Pin1-driven malignancies.
같은 제1저자의 인용 많은 논문 (5)
- A radio-genomics biomarker for precision epidermal growth factor receptor mutation targeting therapy in non-small cell lung cancer.
- SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia.
- Artificial intelligence in colon cancer: A commentary on advances and challenges.
- Spatial blueprint of colorectal cancer identifies Hypoxic CAF program that orchestrates Go-or-Grow decisions and predicts outcomes.
- Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study.